Welcome to 247healthcare

Facebook Twitter Youtube
Active Surveillance Protocols: PRIAS, Johns Hopkins, UCSF & More (2026)

Active Surveillance Protocols: PRIAS, Johns Hopkins, UCSF & More

📅 Medically reviewed: April 21, 2026 | ⏱️ 9 min read | 🏥 Vivekananda Hospital, Hyderabad | 🩺 Urology | Level: Advanced
📖 In this guide

What are active surveillance protocols?

Active surveillance (AS) is an accepted management strategy for men with low-risk and selected intermediate-risk prostate cancer. AS protocols standardise the monitoring schedule, including:

  • Inclusion criteria (who qualifies)
  • PSA testing frequency
  • Digital rectal exam (DRE) frequency
  • MRI timing and interpretation
  • Repeat biopsy schedule
  • Triggers for intervention (treatment)
📌 Key fact: Multiple AS protocols exist worldwide. No single protocol is universally accepted, but all share the goal of avoiding overtreatment.

PRIAS protocol – European, most widely used

The Prostate Cancer Research International Active Surveillance (PRIAS) study is the largest and most influential AS protocol, developed in Europe.

Inclusion criteria:

  • PSA ≤10 ng/mL
  • Clinical stage T1c-T2
  • PSA density <0.2 ng/mL/mL
  • Gleason 6 (3+3)
  • ≤2 positive biopsy cores
  • ≤50% cancer in any core

Follow-up schedule:

  • PSA: Every 3 months for 2 years, then every 6 months
  • DRE: Every 6 months
  • Repeat biopsy: At 1, 4, 7, and 10 years (or earlier if PSA rises)

Triggers for intervention:

  • PSA doubling time <3 years OR
  • Gleason upgrade to 3+4=7 or higher on repeat biopsy OR
  • Increase in positive cores or percentage of cancer
✅ Key feature: PRIAS was the first to use PSA doubling time as a trigger, reducing unnecessary biopsies.

Johns Hopkins protocol – US, strict criteria

The Johns Hopkins active surveillance protocol is one of the oldest and most stringent in the United States.

Inclusion criteria:

  • PSA ≤10 ng/mL
  • Clinical stage T1c-T2a
  • PSA density <0.15 ng/mL/mL
  • Gleason 6 (3+3)
  • ≤2 positive biopsy cores
  • ≤50% cancer in any core
  • Age ≤75 years (historically, now relaxed)

Follow-up schedule:

  • PSA: Every 6 months
  • DRE: Every 6-12 months
  • Repeat biopsy: At 1, 4, 8, and 12 years (or earlier if PSA rises)

Triggers for intervention:

  • Gleason upgrade to 3+4=7 or higher OR
  • Increase in positive cores (>3 cores) OR
  • Increase in percentage of cancer (>50%) OR
  • PSA velocity >0.75 ng/mL/year (secondary trigger)
📌 Note: Johns Hopkins protocol has excellent long-term outcomes with 15-year metastasis-free survival >99%.

UCSF protocol – MRI-based approach

The University of California, San Francisco (UCSF) protocol integrates multiparametric MRI (mpMRI) into active surveillance.

Inclusion criteria:

  • Gleason 6 (3+3) OR Gleason 3+4=7 (selected)
  • PSA ≤10 ng/mL (preferred)
  • No MRI-visible lesion (PI-RADS 1-2) OR targeted biopsy negative

Follow-up schedule:

  • PSA: Every 6-12 months
  • MRI: Every 1-2 years
  • Repeat biopsy: MRI-targeted biopsy if new PI-RADS 4-5 lesion appears; otherwise confirmatory biopsy at 12-18 months

Triggers for intervention:

  • Gleason upgrade to 4+3=7 or higher OR
  • New PI-RADS 4-5 lesion on MRI OR
  • PSA doubling time <3 years (with MRI correlation)
✅ Key feature: MRI reduces the frequency of repeat biopsies and improves detection of clinically significant cancer.

ProtecT protocol – UK trial-based

The ProtecT (Prostate Testing for Cancer and Treatment) trial compared active monitoring, surgery, and radiation. Its AS protocol is widely referenced.

Inclusion criteria:

  • PSA <10 ng/mL
  • Clinical stage T1-T2
  • Gleason 6 (3+3) – 80% of enrollees

Follow-up schedule:

  • PSA: Every 3-6 months
  • DRE: Every 6-12 months
  • Repeat biopsy: At 2-4 years (not protocol-driven; clinician discretion)

Triggers for intervention:

  • Clinician discretion (no strict protocol)
📌 Note: ProtecT showed no difference in prostate cancer mortality at 10 years between active monitoring, surgery, and radiation.

Canary PASS protocol – North American research protocol

The Canary Prostate Active Surveillance Study (PASS) is a North American research protocol that collects standardised data.

Inclusion criteria:

  • Gleason 6 (3+3) – can include Gleason 3+4=7 (selected)
  • PSA ≤20 ng/mL
  • Clinical stage T1-T2

Follow-up schedule:

  • PSA: Every 3-6 months
  • DRE: Every 6 months
  • MRI: At baseline and every 2-3 years
  • Repeat biopsy: At 1, 2, 4, 6, 8, and 10 years (or earlier if PSA/MRI changes)

Triggers for intervention:

  • Gleason upgrade to 4+3=7 or higher OR
  • Increase in positive cores OR
  • PSA doubling time <3 years OR
  • New PI-RADS 4-5 lesion on MRI

Comparison of protocols – inclusion criteria, follow-up, triggers

Not routineNot specifiedClinician discretionNot routineNot specified
ProtocolGleasonPSA (ng/mL)PSA DensityMax CoresRepeat BiopsyMRI
PRIAS6≤10<0.2≤21,4,7,10 yearsNot routine
Johns Hopkins6≤10<0.15≤21,4,8,12 years
UCSF6 (select 7)≤10 (preferred)Not specifiedNot specifiedMRI-targetedEvery 1-2 years
ProtecT6 (80%)<10Not specified
Canary PASS6 (select 7)≤20Not specified1,2,4,6,8,10 yearsEvery 2-3 years

Key differences – PSA thresholds, biopsy frequency, MRI use

  • PSA thresholds: PRIAS and Johns Hopkins use ≤10 ng/mL; Canary PASS allows up to 20 ng/mL.
  • PSA density: PRIAS (<0.2) and Johns Hopkins (<0.15) use PSA density; others do not.
  • Biopsy frequency: PRIAS (1,4,7,10 years); Johns Hopkins (1,4,8,12 years); Canary PASS (more frequent); UCSF (MRI-guided).
  • MRI use: UCSF and Canary PASS incorporate MRI; PRIAS and Johns Hopkins do not (though many centres now add MRI).
  • Gleason 7 inclusion: PRIAS and Johns Hopkins exclude Gleason 7; UCSF and Canary PASS include select Gleason 3+4=7 patients.
✅ Takeaway: Modern AS protocols increasingly incorporate MRI to reduce biopsy frequency and improve cancer detection.

Interactive FAQ – Active surveillance protocols

What is the PRIAS protocol?

European active surveillance protocol with PSA every 3 months, repeat biopsy at 1,4,7,10 years, and PSA doubling time <3 years as trigger.

What are the Johns Hopkins active surveillance criteria?

PSA ≤10, PSA density <0.15, Gleason 6, ≤2 positive cores, ≤50% cancer per core. Repeat biopsy at 1,4,8,12 years.

Does UCSF use MRI in active surveillance?

Yes – UCSF protocol uses MRI every 1-2 years with targeted biopsy of new PI-RADS 4-5 lesions.

How often is repeat biopsy needed on active surveillance?

Varies by protocol: PRIAS (1,4,7,10 years), Johns Hopkins (1,4,8,12 years), Canary PASS (1,2,4,6,8,10 years).

What triggers treatment on active surveillance?

Gleason upgrade to 3+4=7 or higher, increase in positive cores, PSA doubling time <3 years, or new MRI lesion.

Can men with Gleason 3+4=7 go on active surveillance?

Select patients with low volume of pattern 4 may qualify at some centres (UCSF, Canary PASS). Not in PRIAS or Johns Hopkins.

What is the ProtecT protocol?

The active monitoring arm of the ProtecT trial – less structured than other protocols, with clinician discretion for repeat biopsy.

What is PSA density and why is it used?

PSA divided by prostate volume. Used in PRIAS and Johns Hopkins to exclude men with large prostates causing PSA elevation.

Which active surveillance protocol is best?

No single "best" – choice depends on patient factors, centre expertise, and access to MRI. All have excellent long-term outcomes.

🩺
Dr. Surya Prakash B
MS, MCh (Urology) | Consultant Urologist
Vivekananda Hospital, Begumpet, Hyderabad
Medical reviewer for 247healthcare.blog | Review date: April 21, 2026

Disclaimer: This information is for educational purposes and intended for clinicians and researchers. Active surveillance protocols should be individualised.

Scroll to Top